Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000178513 | SCV000230605 | benign | not specified | 2018-05-18 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000178513 | SCV000612903 | benign | not specified | 2016-10-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000539797 | SCV000627226 | benign | Osteogenesis imperfecta type I | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001721123 | SCV000726229 | likely benign | not provided | 2021-04-08 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002277403 | SCV002565510 | benign | Ehlers-Danlos syndrome | 2022-06-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002321706 | SCV002607423 | likely benign | Cardiovascular phenotype | 2020-06-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV001721123 | SCV005040994 | likely benign | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | COL1A1: BP4, BP7, BS1 |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000178513 | SCV005381108 | benign | not specified | 2024-08-14 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001721123 | SCV005879088 | benign | not provided | 2024-04-29 | criteria provided, single submitter | clinical testing |